Conflict of interest
RS
ONCOLOGY
KS has received institutional research funding from Astellas Pharma, Amgen, Chugai Pharma, Daiichi Sankyo, Eisai, Medi Science, Merck Pharmaceuticals, Ono Pharmaceutical, and Taiho Pharmaceuticals; has served in an advisory capacity for AbbVie Inc, Amgen, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Eli Lilly and Company, Janssen, Merck Pharmaceuticals, Novartis, Ono Pharmaceuticals, Pfizer Inc, Taiho Pharmaceuticals, and Takeda Pharmaceuticals; and has received honoraria from Bristol-Myers Squibb and Takeda Pharmaceuticals. BG has received institutional research funding from Boehringer Ingelheim, Glyconex, Helix Biopharma, Hutchison Medipharma, Mirati Therapeutics, NGM Biopharma, Roche/Genentech, Sirnaomics, Taiho Oncology, Toray, and Trishula Therapeutics; consulting fees from BMS, Boston Therapeutics, Exelixis, Foundation Medicine, Ipsen, Pfizer, Roche/Genentech, and Taiho Oncology; and honoraria from BMS, Ipsen, and Taiho Oncology; and has participated in a data safety monitoring board for Roche/Genentech. JT has received consulting fees, honoraria for lectures/presentations and meeting support from Amgen, Astellas, AstraZeneca, BMS, Merck, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, and Servier. RS has received research funding from MSD and Paxman Coolers, has served on the advisory board for Bristol Myers Squibb, Eisai, Bayer, GSK, Merck, MSD, Novartis, and Taiho; has received honoraria for talks from AstraZeneca, BMS, Eli Lilly, DKSH, MSD, Roche, and Taiho; and has received travel support from AstraZeneca, DKSH, Eisai, Roche, and Taiho. MF has received institutional research funding from Amgen, Inc., Bristol Myers Squibb, Genentech, Novartis Oncology, and Verastem; consulting fees from AstraZeneca, Incyte Corporation, PsiOxus, and Taiho Oncology; honoraria from Guardant360, and has participated in an advisory capacity for Amgen, Inc., Bayer Corporation, GlaxoSmithKline, Mirati Therapeutics, Nouscom, and Roche/Genentech. LM is a consultant statistician for Taiho Oncology, Inc. and is paid by Taiho Oncology Inc. KAB is an employee at Taiho Oncology and owns stock of Eli Lilly. MG has served in an advisory capacity for Amgen, Eli Lilly and Company, Merck Pharmaceuticals, Roche, and Servier Pharmaceuticals.